This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 19-22, 2025 | In-Person + Digital
Manchester Grand Hyatt San DiegoSan Diego, CA

Yogesh Sanghvi, PhD
President at Rasayan Inc.


In 1981, Dr. Sanghvi received his Ph.D. in organic chemistry from National Chemical Laboratory (Pune, India), where he worked on the synthesis of natural products. From 1982 – 1985, his post-doctoral research on the synthesis of modified nucleosides was carried out at the University of London with Professor C.B. Reese. In 1986, he joined the Nucleic Acids Research Institute at ICN Pharmaceuticals, California. At ICN, he was involved in the design, synthesis and screening of novel nucleosides and nucleotides as antiviral and antitumor agents. From 1989 – 2003, he worked at Ionis Pharmaceuticals, California. The focus of his research at Ionis has been on the discovery, development and manufacture of oligonucleotide-based therapeutics, DNA and RNA modifications in combinatorial and diagnostic research.

Dr. Sanghvi has authored/co-authored over 210 scientific publications in leading journals, including several book chapters and has co-inventorship of more than 40 patents. Throughout his professional history, he has attended and made numerous presentations at local and international scientific meetings and has successfully organized several symposiums. He is an editor of two books entitled Carbohydrate Modifications in Antisense Research and Palladium-Catalyzed Modification of Nucleosides, Nucleotides and Oligonucleotides. He is also a member of the editorial board for Current Protocols in Nucleic Acid Chemistry, a Wiley publication.

In May 2003, he founded Rasayan Inc., a company focused on consulting, outsourcing services and supply of products related to the nucleic acid field. Rasayan is engaged in the strategic planning, securing raw materials for manufacture of oligonucleotide-based drugs on large-scale, experimental design, optimization of synthesis and purification protocols on lab scale to kilo scale, including process chemistry. Dr. Sanghvi is also a founding member of Sapala Organics, a CRO/CMO located in Hyderabad, India. Currently, he serves as President of Sapala business in North America looking after sales and marketing for the company. His specific interests include design, synthesis, chemistry and biochemistry of novel carbohydrates, nucleosides, nucleotides, and oligonucleotides for their application in therapeutics, combinatorial chemistry, and medical diagnostic research.

Agenda Sessions

  • Chairman’s Remarks: Emerging Trends in Oligonucleotide Synthesis